Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. ARM
4. BROS
5. QCOM
6. EXPE
7. PAYC
8. APP
9. FSLY
10. CPAY

Go back to Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M

Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights

November 8, 2021 6:35 AM EST

Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recommended progression to second half of study

Dosing initiated in Phase 1 study of potential first oral aminoglycoside antibiotic drug MAT2501 (oral amikacin)

Accomplished biotechnology executive, Kathryn Penkus Corzo, joined Companys Board of Directors

Management to host conference call today, Monday, November 8th, at 8:30 a.m. ET

BEDMINSTER, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) --... More